Category Archives: Immunology

Kawasaki syndrome

A syndrome of unknown cause, characterised by persistent fever, conjunctivitis and mucosal changes eg strawberry tongue in a young child who has often been treated empirically with antibiotics without improvement, and is invariably miserable. Potentially complicated by coronary aneurysms, which may be fatal. Kawasaki’s is the leading cause of acquired heart disease globally after rheumatic fever, and is the leading cause in the North.

It is a vasculitis affecting medium sized arteries, and other arterial vessels down to capillary size. Second most common vasculitis in childhood, after IgA vasculitis.

Was thought to be a superantigen disorder, ie with no specific infectious agent, polyclonal B activation – coronary aneurysms have been seen in other superantigen diseases eg toxic shock, have also been reported in meningococcal septicaemia. But now thought to be conventional, but unknown, infectious trigger.

Similarities with COVID PIMS-TS.

Genetics important, risk higher in East Asian immigrants, plus family history, single nucelotide polymorphisms found in 6 genes including FcγR2a, caspase 3 (CASP3), and human leukocyte antigen class II.

Clustering has been shown (Knox test significant within the space-time interval of 3 km and 3-5 days) which suggests an infectious trigger [PIDJ 27(11):981-985, Nov 2008]. TNF alpha seems important, in an animal model, knock out mice or anti TNF treatment prevents aneurysm development.

The underlying pathology is a vasculitis, and although coronary disease is the best recognized there is increasing evidence that other medium sized arteries are affected with descriptions in the literature of peripheral gangrene and cerebral infarction. Proposed model includes necrotizing vasculitis, plus chronic/subacute vasculitis, 2 weeks after onset and sometimes lasting months, with a unique type of luminal myofibroblastic proliferation. 

Epidemiology

More common in males, peak age 18-24 months.

BPSU Kawasaki – 553 cases were notified: 389 had complete KD, 46 had atypical KD and 116 had incomplete KD!  Median time to IVIG in those with Coronary artery aneurysms (CAAs) was 10 days cf 7 days for those without.  Rate of CAA in under 1yr was 39%.  19% overall had CAA despite treatment.  Associated with low albumin, and incomplete.  Only 1.6% developed giant aneurysms, which have the worst prognosis, of course.

Risk of CAA estimated at 20-40% if untreated.  [Archives PMID 30104394]

Incidence in west seems to have plateaued, after decades of increase (?ascertainment bias). 10-20x higher rate in NE Asia (Japan, Taiwan, Korea), plus continues to increase! 1% of all Japanese kids will have had KD by age 10. But unrecognized before 1950, whereas pathological specimens in UK from over a 100yrs ago show same process.

Less complications in Asia!  Better diagnosis? Arguably all European cases could be considered high risk…

Japan has had 3 epidemics, the only country to have had them, but none since 1986.

Data from China and India indicate increase, with only a few case reports prior to 1990. Rate in Chandigarh equivalent to UK now, presumably underestimate, but already outnumbers rheumatic fever cases.  Also high rate in Kerala, but related to affluence or health care availability?    Rate in Shanghai approaching NE Asia rate. Rate in Hong Kong has tripled in 20 years. Will become the predominant cause of acquired cardiac disease?

Association between seasonal wind patterns in Pacific and KD rates in Japan, California and Hawaii! May relate to infectious agents.

[Singh S, et al. Arch Dis Child 2015;100:1084–1088. doi:10.1136/archdischild-2014-307536]

Case definition

(American Heart Association):

  • Fever of 5 days duration or more
  • plus 4 of the following (ie only drop 1):
    1. Conjunctivitis: Bilateral, bulbar, without exudate
    2. Lymphadenopathy: Cervical, >1.5 cm
    3. Rash: Polymorphous, no vesicles or crusts
    4. Changes of lips or oral mucosa: Red cracked lips; “strawberry” tongue; or diffuse erythema of oropharynx
    5. Changes of extremities:
      • Initial stage, erythema and oedema of palms and soles
      • Convalescent stage (about two weeks) periungual desquamation of fingers and toes
Images from Circulation journal 2017

These are all acute febrile stage symptoms, first 2 weeks (besides the desquamation) – but not necessarily all at the same time, sometimes only on history. After 2 weeks, persistent irritability, poor appetite, conjunctival injection. If still febrile at this point then high risk of cardiac complications. Any coronary artery ectasia or aneurysms may enlarge from week 4-8. Ectasia may resolve.

In Japan, prolonged fever is one of the optional features – 1/3 of Japanese children get IVIG before day 4! McCrindle guideline (AHA, 2017) suggests complete Kawasaki disease may be diagnosed with 4 days (possibly even 3 days) fever if one of the features is peripheral erythema/swelling.

Many people would also diagnose if only 3 of these features plus coronary artery aneurysms detected. Lymphadenopathy is the least common feature (?easy to miss) – esp uncommon in younger children. Perineal desquamation is also quite characteristic.

There may also be abdominal pain, diarrhoea, hepatitis/pancreatitis, arthralgia/arthritis, aseptic meningitis, facial nerve palsy and pneumonitis (with or without pulmonary nodules). There may be a murmur (mitral incompetence), and myocarditis can occur but it is rarely severe. CXR changes (nodules, peribronchial and interstitial infiltrates). Aortic root enlargement. Desquamation in groin. Hydrocoele and gall bladder hydrops! Anterior uveitis. Renal involvement, encephalopathy have been described, macrophage activation syndrome has been reported rarely.

Pitfalls –

  • infants, adolescents (“glandular fever”).
  • Signs change over time – rash fades, desquamates, then nail changes but similarly lymph nodes, mouth changes.  So at any one time only a few features may be evident – especially beyond first week.
  • Normal or low platelets (actually a high risk feature in some scoring systems)
  • Sterile pyuria (“UTI”), “aseptic meningitis”
  • Presentations with myocarditis, surgical abdomen (GI vasculitis)
  • Single dose of IVIG without response does not mean diagnosis is wrong, in fact means more aggressive treatment required.
  • Beware positive cultures putting you off diagnosis! Might be triggering infection! Even Strep, adenovirus

Tips –                           

  • BCG reactivation as a clue
  • Arthritis as a clue
  • Axillary/inguinal aneurysms on examination? [Janet G-M]
  • Repeat echo early, especially where diagnosis still not clear cut. Cardiology need chasing!?
  • IVIG raises ESR! Don’t interpret as treatment failure!
  • Incomplete/uncertain have highest risk of complications! So consider if fever >=5/7 with 2 criteria, or infants [only infants?] with fever >= 7/7 without necessarily any criteria, but no other explanation! CRP>30 and ESR>40 should trigger further assessment eg echo and use of additional lab criteria eg anaemia, high platelets (>450 beyond day 7, but also <140), high ALT, high WCC (>15), low albumin (<30) . Echo if CRP/ESR low but peeling. 3 or more additional lab criteria sufficient to make diagnosis.

Many of the clinical features of the disease are outbreak dependent with a different spectrum of clinical findings in one mini-outbreak compared with another, and with cases having similar clinical phenotypes clustering temporally.

So consider echo in any young child with persistent fever.

The term atypical or incomplete Kawasaki disease is used for cases without the required number of features. Whether this is the same disease or not is unclear; there will undoubtedly be some cases that overlap with other systemic vasculitides eg polyarteritis nodosa (PAN). In PAN, mucocutaneous changes are uncommon, whereas renal disease is common. Gall bladder hydrops appears to be unique to Kawasaki’s. On the other hand, having a rigid case definition is perhaps unhelpful since incomplete cases are often seen, particularly in infants, and are associated with a delay in diagnosis and worse prognosis. Under the age of 3 months, the majority of cases with coronary aneurysms have atypical presentations.

McCrindle AHA guideline suggest incomplete KD should be diagnosed where:

Differential diagnosis

Investigations mainly help exclude alternative diagnoses. Infection may have triggered KD so may need to treat for both – antibiotics if concern – get cultures. Typically with the disease itself test results simply indicate systemic inflammation and can be useful for monitoring response to treatment. Hence there are usually elevated white cells, platelets, ESR and CRP, ferritin/coag (MAS?), troponin (myocardial involvement?), D-dimers, LDH. Liver function tests are often mildly deranged. Low sodium and albumin suggest vascular leak. The ECG may have PR interval changes, and ST segment or T wave changes. Echocardiography (ideally within 2 weeks of onset of fever but as soon as possible) may reveal dilated, ectatic coronary arteries or frank aneurysms.

Consider CXR, Abdo USS (incl gall bladder).

Treatment

SPARN 2024 guidelines (based on AHA) advises taking serum for storage if possible, prior to IVIG. Refer for echo within 1-2 days assuming normal ECG and CXR. Admit under Infectious diseases or Rheumatology unless cardiomegaly, abnormal ECG, heart failure or giant aneurysms.

As with Eleftheriou (2013) guidelines, methylprednisolone in addition to IVIG/aspirin if high risk viz infants, severe inflammation (CRP>100, liver dysfunction, hypoalbuminaemia, anaemia), shock or HLH, evolving anuerysms/ectasia, failed IVIG – consider if thrombocytopaenia, late presentation). Infliximab is included as an option for resistant or recrudescent disease. Of course, diagnosis should be reconsidered if response to treatment is poor.

Standard treatment is with intravenous immunoglobulin (IVIG) 2g/kg over 12 hours, ideally within the first 7-10 days of the illness, and with aspirin (high initial dose 30-50 mg/kg/day in 4 divided doses orally during the acute phase – AHA still recommends before switching to low dose but insufficient evidence of benefit). This combination reduces the risk of aneurysm formation from 25% to 9%. Most will respond to a single dose, but about 20% will require a second dose. Add steroids if not given already and consider second dose if persistent fever and/or failure of CRP to fall at least 50% within 48 hours. Of these, only a half will then defervesce.

IVIG side effects – fever, headache, joint pain, aseptic meningitis, BBV, allergic reaction (?), raised ESR. Remember to defer immunisations for 3 months.

Once defervescence has occurred, the aspirin dose can be reduced to an anti-platelet dose of 3-5mg/kg/day (max 75mg). Aspirin is stopped after 6 weeks unless aneurysms found.

Duration of fever is the most powerful predictor of poor coronary outcome (one additional day of fever increasing the odds of aneurysm development by 3-5x). Delayed diagnosis is usually a reflection of slow evolution of criteria rather than atypical presentation – in that study, diagnosis after 10 days had a 2.8x higher risk of aneurysms (although they also had higher platelet counts). [Pediatrics. 115(4):e428-33, 2005. PMID 15805345]

Methylprednisolone treatment is 0.8mg/kg BD IV for 5-7 day or until CRP normal, followed by Prednisolone 2mg/kg weaning over 2-3 weeks. Other regimes are Methylpred 10-30mg/kg IV OD for 3 days followed by prednisolone.

In Europe steroids reserved for worse cases – but by epidemiology, all European cases could be considered high risk?? 39% of under 1yrs had coronary aneurysms (BPSU study). Europe Kawasaki trial in progress (KDCAAP) – Adding immediate corticosteroid treatment to standard of care IVIG and aspirin.

Scoring

Several scorings systems have been developed to predict IVIG resistance and poor outcome. Kobayashi criteria used to predict IVIG failure (5+ points), but more sensitive in Japanese populations – just 33% in Non-Japanese, with 87% specificity:

  • Age<12 months (2 points)
  • Fever <=4 days (1 point)
  • Na<=133 (2 points)
  • ALT>=100 (1 point)
  • Plts <300 (1 point)
  • CRP>10 (1 point)
  • >80% neutrophils (2 points)

Echo

ECG and echo should be done as soon as possible but should not delay treatment. Urgent if heart failure, cardiomegaly on CXR or ECG abnormalities. If first echo is normal and CRP normal after 1 week, repeat scans recommended at 2 and 6-8 weeks. But chase cardiology to repeat early if diagnosis unclear.

Those with Z score more than 10 (“large”) have 25% risk of coronary event within 10yrs (girls), 50% (boys)!

Most aneurysms will resolve over time, unless they are giant (>8mm). Serial echocardiography should be done to monitor resolution. Evidence of subacute chronic vasculitis for months (post-mortem cases) so move now to infliximab treatment etc after initial immunosuppression.

Warfarin should be considered for giant aneurysms, with initial heparinization to prevent paradoxical thrombosis, although its potential for complications in young children is significant. Stress testing and angiography may be appropriate. Aspirin can be discontinued if aneurysms resolve, but it is likely that the atherosclerosis risk remains high and life long follow up to address other risk factors is sensible.

Mortality in the UK has been as high as 3.7%, but is much lower in Japan.

[2020 ArchDisChild Ed and Practice Kelly]

[2017 AHA guidelines]

[Eleftheriou Arch Dis Child 2014;99:74–83, J Paed and Child Health 49 (2013) 614–623]

UK vaccine schedule

Changes depending on availability (and cost) of new vaccines, changes in epidemiology.  And levels of public acceptance!  Recommendations made by JCVI (Joint committee on vaccines and immunization).  Most recent change is introduction of MenB (Bexsero).

  • At, 2, 3 and 4 months, a 5 in 1 vaccine containing diphtheria/tetanus/pertussis with polio and Hib is given (Pediacel).
  • Prevnar (pneumococcal conjugate, PCV-13) is given at 2 and 4 months with a booster at 12-13 months
  • MenC now given at 3 months only (other 2 doses dropped), in between Prevnar, with a booster at MMR time.
  • Oral rotavirus vaccine is now given at 2 and 3 months.
  • Bexsero (MenB) vaccine is given at 2 and 4 months, with booster at 12-13 months.

At 12-13 months, MMR – along with boosters of Hib/MenC (Menitorix), Prevnar and MenB

Annual nasal influenza vaccines are being phased in over next few years, currently all primary school and ages 2-4yrs.  Will eventually be all up to 16.

At 3yrs 4 months- 5yrs, preschool booster – DTP/Polio (Repevax, no Hib) and MMR again.

At 13yrs, BCG has been dropped as a universal vaccine. There is now a booster of MenC, along with Tetanus, diphtheria (low dose) and polio (no pertussis, Revaxis).

Girls between 12 and 14yrs get 2 doses of HPV vaccine, at least 6/12 apart.

Over 65s get scheduled PPV (pneumococcal polysaccharide, once) and annual influenza.

Over 70s get a single Shingles vaccine.

The acellular pertussis vaccine (3 or 5 antigens cf 3000 in whole cell) is associated with less reactions (but less effective and immunity shorter lasting); IPV (injectable) polio vaccine has same efficacy as OPV (oral, live, Sabin, herd immunity), plus no vaccine associated disease.

These newer vaccines have fewer reactions, and do not contain thiomersal. Not that there’s any evidence against mercury, but plan to eliminate it has been in place for several years.

There was also an issue with loss of Hib efficacy when using 3 in 1 DTP for primary immunizations, which is not seen with Pediacel.

No individual boosters for tetanus are available. Choice is between Infanrix (DTaP), Repevax or Revaxis.

Instead of BCG for all adolescents, risk factor approach introduced: BCG will be offered to all infants in health boards with incidence over 40/10 000 (none in Scotland), and to those with parent or grandparent from high incidence area.

Rhinitis QOL

You can just use generic SF-36 questionnaire, statistically significant differences between patients and controls were observed in seven of nine dimensions in the SF-36 questionnaire. Or RQLQ score (mini-form also available). (J Allergy Clin Immunol 1997;99:S815-9.) SF-36 particuarly highlights mental adverse effects, RQLQ highlights sleep disturbance.

Quality-of-life parameters measured by the RQLQ questionnaire:

  • Sleep – Lack of a good night’s sleep, Wake during the night, Difficulty getting to sleep
  • Non-hay-fever symptoms – Tiredness, Fatigue, Worn out, Reduced productivity, Poor concentration, Thirst, Headache
  • Practical problems -Need to blow nose repeatedly,Need to rub nose/eyes,Inconvenience of having to carry tissues or handkerchief
  • Nasal symptoms -Stuffy/blocked,Sneezing,Runny,Itchy
  • Eye symptoms – Itchy, Watery,  Swollen,  Sore
  • Emotions – Irritable,  Frustrated,  Impatient or restless, Embarrassed by nose/eye symptoms
  • Activities eg  Bicycling Cooking Dancing Doing home maintenance Doing housework Gardening Eating out Jogging, exercising, or running Attending public events Driving a car Watching TV or a movie Singing Mowing the lawn Playing with pets Doing regular social activities Talking (public speaking) Studying or doing homework Taking a test or quiz Visiting friends or relatives Going for a walk Having sexual intercourse Carrying out activities at work Reading Playing sports

Juniper and Guyatt

 

Hymenoptera venom allergy

ie bee/wasp. A common cause of anaphylaxis, and interestingly, not related to atopy.  Reactions can be immunological (IgE or non IgE), or non-immunological (toxic). 

Severe reactions related to allergy but also number of stings, insect type, cardiovascular/respiratory disease and also mastocytosis.

Whether it is bee or wasp or other is sort of important, from the point of view of cross reactivity and risk. Several major allergens eg hyaluronidase, phospholipase A2. Apid (bee) hyaluronidase is 50% identical to vespid, so good chance of being allergic just to one and not the other.  Vespids subdivides into Vespa=hornets (found in UK, biggest, 35mm, reddish brown head); Vespula=wasps; and Dolichovespula (“short headed wasps” – harder to distinguish, “shorter distance between eyes and upper jaws”!). These 3 vespid types cross react strongly, so likely to be allergic to all.   “Yellowjacket” is American name for wasps.

Bumblebee PLA2 is 53% identical to honeybee PLA2, so not necessarily cross reactive!

Polistes=”paper wasps”, distinct from other vespids, Southern Europe only (so far) – large, long legs, not esp colourful. Limited cross reactivity to wasps/hornets, thankfully. 

Ants are also hymenoptera!

Clinical

  • “Normal” local
  • “large” local = >10cm swelling, plus >24hrs. Blisters sometimes present). Mech prob toxic, but sometimes evidence of IgE mediated mechanism,
  • systemic toxic (haemolysis, nephropathy, coagulopathy – rare, usually from multiple stings)
  • systemic +/- anaphylaxis [usually igE, rarely short term IgG, or complement activation by IgG-venom complexes]
  • (plus “unusual”).

Wasps and hornets not as fuzzy as bees. Was a barb left behind? Bees, not wasps. Multiple stings at the same location? Wasp, not bee.

Systemic reactions should be assessed by allergy specialist, including skin prick tests, total IgE and baseline tryptase tests.

  • rapid onset generalized urticaria and/or angio-oedema,
  • bronchospasm
  • laryngeal oedema
  • hypotension (collapse, loss of consciousness).

Hypotension is the dominant feature and may occur alone.

Risk factors for outcome of anaphylactic reaction:

  • age,
  • CVS disease/drugs,
  • insect type,
  • time interval between stings (short interval increases risk of systemic reaction to second sting),
  • number of stings,
  • severity of previous reaction,
  • elevated mast cell tryptase, else known mastocytosis.

Bee allergic at higher risk of systemic reaction than vespid allergic. Hornets risk seems to be esp high.

Frequent stings can induce tolerance (but probably needs more than 200 per year!). 

Venom IgE >1 had 12x risk of anaphylaxis (beekeepers, regardless of previous history). Pos skin test (adults without history of anaphylaxis) had 17% risk, cf 0% of neg skin test [so negative test v reassuring, but risk still low even if you are pos, which would be unusual in most kids]

Majority of fatalities have significant cardioresp co-morbidity. 40-85% of fatal reactions had no documented history of previous anaphylactic reactions.

Mild systemic reaction previously gives 18% risk of subsequent systemic reaction (kids). Compare after large local – 5-15%, so sl higher but not much. Children tend to have mild systemic reactions, cf most adults get resp or CVS symptoms.

Several case reports of severe reactions in mastocytosis; even without mastocytosis, high basal tryptase seems to increase risk of anaphylaxis.

Testing

Even when SPT pos, 25-84% of subjects do not react to subsequent sting!
 
Similarly, up to 22% of those with neg tests will have systemic reaction in future. [Allergy 2005: 60: 1339–1349]

Test all with systemic reaction, not recommended otherwise. If not witnessed? Only really useful to distinguish bees vs wasps (says the Anaphylaxis Campaign)!? Unless you’re a bee keeper, wasps are the one you are most likely to be stung by.

Skin prick testing more sensitive/specific. Probably sensible to leave a month or two between the event and testing else false negative due to “refractory period”. This period can sometimes be longer so consider repeating if good history.  If negative, try IgE; then intradermal ( with 0.001-1mcg/mL solution  -seems to have higher sensitivity).

Stepwise skin testing with 0.01-100mcg/ml solutions incrementally recommended. 

Some people will be persistently negative on testing, probably due to being allergic to an unusual protein. Consider systemic mastocytosis as a differential. 

Family history of venom anaphylaxis is a common cause of concern.  Unfortunately, there is no point testing other family members – you are unlikely to test positive if you have never been stung.

Specific IgE levels (if you do test positive) only vaguely correlate with anaphylaxis risk (not statistically significant) [Allergy 62(8): 884-889, August 2007]. However, having low total IgE (<50kU/l) predicts anaphylaxis (not v sensitive, only explains 25%), whereas high total IgE (>250) protects (very specific)!

Serum IgE appears within a few days of sting, begins to decline at a variable time – wait long enough, and no IgE may be detectable. Double positivity to bee/vespid could be genuine cross sensitivity but might be cross reactivity of IgE to epitopes of unknown clinical significance.

Baseline serum tryptase over 11 has high positive predictive value for anaphylaxis but is not very sensitive. Good for picking up mastocytosis though!

So you may be able to find the occasional person who seems to be at particular risk (high tryptase, low total IgE), or relatively protected (high total IgE) but you will still miss most cases of anaphylaxis.

Immunoblotting, basophil activation tests etc sometimes used if others tests negative. But sens/spec generally not known.  

High basal tryptase may increase risk of reactions with VIT but still indicated.

Give allergy plan and prescribe Adrenaline if severe systemic reaction, consider if moderate. 

If successful VIT, still get adrenaline if further symptoms, continued exposure, high tryptase.

[BSACI guidelines – Clinical & Experimental Allergy. Volume 41, Issue 9, September 2011, Pages: 1201–1220 doi/10.1111/j.1365-2222.2011.03788.x]

Immunotherapy

See Venom immunotherapy.

Honey allergy

Reported, in most cases appears to be due to pollens contained in the honey, or at least allergens highly cross reacting with pollens. But in a minority, does appear to be due to bee derived components. Type of honey will determine what pollens are contained in it; commercial honey often contains v low amounts due to production techniques.

Prevention

Risk of sting related to zone, climate, temperature, outdoor activities etc. Some repellents marketed as effective against wasp/bee (IR3535 (Ethyl butylacetylaminopropionate) eg Jungle Formula “outdoor & camping”) but most creams/sprays (DEET, Citronella oils etc) are for biting insects (midges, mosquitoes etc), not stinging. Bees/wasps generally not interested on landing on your skin anyway!  Sting because they are threatened!  

Avoid opening windows, avoid rubbish bins, tidy away food/drink (esp sugary) .  Calmly walk away!

Keep skin covered. Keep surfaces, mouth/face/hands clean of food residues after eating!!!

Raid-type killer sprays for environment.

Patient Support

Anaphylaxis campaign have insect venom leaflet.

Ocular allergy

Differential of eye allergy includes tear film dysfunction, infection, autoimmune/inflammatory conditions, blepharitis, dry eye.

Severe -2 of vision disturbance, impairment of daily activities (leisure, sport, school, work); troublesome symptoms.

Perennial conjunctivitis usually related to house dust mite (HDM), animal dander, moulds else multiple. Itch characteristic, as per seasonal conjunctivitis, findings non-specific eg tearing, redness, eyelid swelling, small papillary hypertrophy of tarsal conjunctiva. Neither has corneal involvement.

Beware pain, photophobia, visual disturbance, grittiness or foreign body sensation.  These can indicated Vernal keratoconjunctivitis, which does affect the cornea (warm climates eg Mediterranean/Africa): typically boys aged 4-12yrs, T cell and IgE combined, improves after puberty. Severe itching, exacerbated by nonspecific stimuli eg wind, dust, sun. Cobblestone appearance of tarsal plate (ie inside upper eyelid) else limbic thickened and opacified +/- white/yellow gelatinous deposits (more typical of tropical form).  Can get corneal ulcers.

Atopic keratoconjunctivits is also rare, the eye can be the only affected area cf atopic dermatitis. Hall mark is fissured eyelid. Staph colonization contributes. Limbus and cornea can be affected.

Giant papillary – associated with contact lenses.

Contact blepharoconjunctivitis is eyelid itching, oedema, eczema with less in the way of conj redness.

Investigations for ocular allergy

Skin prick testing incl moulds. Consider latex. Else IgE.

Conjunctival provocation test can be done with standardized allergens – defer if on local or systemic antihistamines or anti-inflammatories, contra-indicated if uncontrolled asthma.  Ideally when asymptomatic and eye not inflamed! Dilute extract to obtain several lower concentration solutions (last up to 6 hours at room temp).  Administer 20microl dose at 30 min intervals at infero-external quadrant of right eye.  Left eye is control!  Have local antihistamine and steroids available, in addition to usual systemic medicines.  Only 1 reported case of anaphylaxis!

Patch test for non-IgE. Else Conjunctival cytodiagnosis eg eosinophil infiltrates.

Treatment and prevention –

  • Avoid allergens, protect eye with sunglasses.
  • Lubricants and cold compresses are good.
  • Topical antihistamines eg azelastine, olapatadine but also Lodoxamide, ketotifen.
  • Mast cell stabilizer (ie cromoglycate) needs 2/52 preloading and multiple doses per day, plus stings! So poor compliance.
  • Systemic antihistamines if other symptoms else may be excessively drying.
  • Topical steroids should be avoided except where cornea involved, ie VKC, AKC, and then only in short pulses.  Twice daily steroids for a month or more raises concern about glaucoma, cataracts.
  • Ciclosporin drops oily, supply probs – veterinary products used! Tacrolimus not available in drops; cream burns a little but gets better.

Nasal steroids work well for eye symptoms and appear to be safe.

For blepharitis, eyelid hygiene, emollients, 1% hydrocortisone.

[Leonardi, Allergy 67 (2012):1327]

Adrenaline Autoinjectors

viz Epipen, Jext, Emerade, AUVI-Q etc.

Who needs one?  Anyone at risk of anaphylaxis, is the simple answer.  But there are no reliable ways of identifying who is at risk of anaphylaxis!

There is also a big problem with them not being used even when they are available.

Who needs one?

EAACI position paper – see Anaphylaxis management.  Only a couple of absolute indications, otherwise a risk assessment. 

2021 Expert working group – MHRA set up after further coroner’s inquests into anaphylaxis deaths, following European safety review in 2015.  Recommendations are:

  • Early adrenaline.  Which means teaching families/children recognition of signs. 
  • Need for 2 pens emphasized.
  • Brand specific training
  • Key messages on packaging eg “don’t delay”, “use second pen if necessary”
  • Posture detailed – “lie down with legs up”, “sit up if breathing difficult but don’t change position suddenly”, “stay lying down [regardless of whether you feel better or what people tell you to do]” 
  • Wider availability of AAIs in public places likely to be beneficial but this would require legislative amendment as well as public training, and concerns about storage conditions and supply would need to be addressed.
  • Dosing errors in hospital common, but given pressure on AAI supply may not be great solution. Other solutions would be labelled kits, pre-filled syringes, different system of labelling adrenaline (!).
  • Reporting of device related adverse events, and anaphylaxis events (including re-establishment of fatal anaphylaxis registry).

Technique

Patient should lie down (but if respiratory symptoms then may be more comfortable sitting). Video available at Epipen and Jext websites. 3 minute training video with more explanation on Youtube. Or scan this:

  • Remove safety cap (Blue for Epipen, Yellow for Jext).
  • Hold in fist, avoid touching ends to reduce risk of accidental self injection.
  • Jab orange (Epipen) or black (Jext) tip firmly into upper outer thigh, through clothing if necessary but avoid seams and pocket contents eg coins, mobiles – clicks as it activates.
  • Hold for 3 secs (Epipen), 10 secs (Jext).
  • Previous advice was to rub area (probably now white) vigorously for 10 seconds. Adrenaline causes vasoconstriction in skin, but vasodilatation in muscle so should be absorbed as long as IM.  Not specified now.
  • Phone 999.
  • Dispose of device safely (device is self sheathing).  Note that some drug left behind, which is normal, and that pen cannot be reused!).
  • Repeat after 5 minutes if necessary. Use a different leg!

Training checklist (from GOS):

  • When to use it
  • How to use it
  • When to carry it ie at all times!
  • Storage/disposal – should be protected from heat and light
  • Expiry date – reminder service available from support website (link above)
  • Friends/babysitters aware?
  • School aware?
  • School trained and have pen?
  • Medicalert bracelet/watch/necklace – other brands available

They come in two different doses – standard strength is 0.3 mg, there is  a 0.15 mg strength prescribed for younger children (15-30kg). Emerade (not currently available) gcomes in a 0.5mg strength for adults and children over 12, which is a more appropriate dose for bigger people viz over 60kg.

If patient is under 15kg,  CYANS guidance is that over 7.5kg, the potential benefit outweighs the risk.  For those under 7.5kg, need to balance risk of anaphylaxis with risk of drug error from drawing up adrenaline from vial with syringe and needle.

Epipen has 18 month shelf life, self sheaths, and has a window to show ready to use. Blue safety cap, orange needle end. JEXT pen similarly self sheathing, coloured window to show whether it is live or not, 24 months shelf life. Yellow safety cap, black needle end. Same needle length.

Anapen has been discontinued.  Had a shorter needle, different technique – remove caps from both ends, hold against leg, put your thumb over the end and press red button.

Emerade pen has safety cap over needle end – this is different from the other types but is logically simpler. Needle is 25mm long cf 15mm Epipen/Jext.  Currently off market due to reliability of activation concerns.

Number of Pens

2018 MHRA review recommends 2 pens available at all times, and made the recommendation directly to families so they can demand them from their doctor!  BSACI (2016) suggested children should in most cases just get 2 pens, 1 for home and 1 for school, but this was contradicted by later European Medicines Agency (EMA) and previous NICE guidance.  Still not clear why they should ever by prescribed in single rather than twin packs…

European medicine agency review (legally binding in EU) concluded that:

  • due to uncertainties about the site of drug delivery and the speed of adrenaline action within the body, it is recommended that healthcare professionals prescribe 2 auto-injectors, which patients should carry at all times
  • the needle length of the device is now stated in the product information because this may be an important factor for the prescriber to consider when choosing a suitable auto-injector
  • the training of patients and their carers in the correct use of the product is important and manufacturers were required to update their educational materials
  • manufacturers should carry out studies in humans to more fully understand when and how much adrenaline reaches the blood stream, and how quickly and effectively it acts on body tissues when given through an auto-injector

EAACI guideline says number of pens should be guided by individual assessment, and BSACI also allow that 2 pens may be more appropriate in some cases, eg obesity, previous need for 2 doses, remoteness etc. There has been good evidence published indicating that one-third of children with anaphylaxis require a second dose of epinephrine (Kornblat P, et al Allergy Asthma Proc. 1999; 20: 383–6), and deaths have occurred despite a single injection, but most of these reports describe subcutaneous adrenaline use, rather than intramuscular use. Dose is more likely to be an issue with big teenagers (eg over 45kg).

If you carry your pen, know how and when to use it, then you are doing to do significantly better if you have a bad reaction than most other people, so don’t get too hung up on how many pens!

Spare pens in school

New legislation (2017) allows schools to obtain without prescription spare pens.  These can be used if the pupil’s own pen is not immediately available or already given.  Note that children with food allergies are not always prescribed adrenaline auto injectors but may still be at risk of anaphylaxis.  The spare pen can be used in such children if:

  • The child’s care plan confirms child is at risk of anaphylaxis
  • A health care professional has authorised use of the spare pen in an emergency
  • The child’s parent/guardian has provided consent for a spare pen to be administered

Note that advice on using pens can be given over the phone by emergency services, if it is made clear pens are available.

Further information about spare adrenaline pens, and advice on reducing the risk of reaction sin school, treating reactions in school, staff training etc can be found at https://www.sparepensinschools.uk/

Needle length

Doing ultrasounds of thighs shows that in a significant proportion of people, including children under 5 with high BMI, the distance to muscle is more than 15mm (and not including any clothing). 82% of the obese children studied had skin surface to muscle depth greater than needle length. This was only true for 25% of the non-obese children. 3/4 the way down the thigh, only 17% of obese children and 2% of those not obese. Arkwright, Royal Manchester Children’s Hospital –  2013 Annual AAAAI meeting.

Some suggestion from injection models that “jet” of adrenaline penetrates significantly deeper than needle alone, that the angle, force used, whether the device is spring loaded or not, all potentially affect depth. So concerning, especially given the cases where multiple injections have failed to prevent death (eg Natasha Ednan-Laperouse).

Emerade had longer needle (25mm) but not currently available.  So inject in lower lateral thigh?

2015 European medicine agency review discussed above concluded that training remains the paramount issue, although further research into needle length should be done.

2021 Review found that blood adrenaline levels actually higher after Epipen and Jext cf

Failure to use

In a prospective UK study of children prescribed AAI for at least a year, the most common reasons given by patients for not using their AAI (245 episodes of anaphylaxis, AAI used in only 16.7%) were ‘thought adrenaline unnecessary’ (54.4%) and ‘unsure adrenaline necessary’ (19.1%). Device not being available only mentioned in 5%.

In 2002 Australian retrospective study of patients with previous anaphylaxis, shortness of breath usually recognised as anaphylaxis symptom but less commonly upper airway or cardiovascular symptoms/signs. Half forgot the need to remove safety cap and hold for 10 seconds in scenario. 71% of anaphylactic reactions were not treated with AAI, even though AAI was available in most cases. About half of those needed adrenaline treatment in hospital (which was rare in AAI treated cases).

In a 3 year Canadian study of 1500 ED episodes, almost 50% of adults were not treated with epinephrine in or outside of the hospital.  Slightly better for kids, 28.7%.  Almost all of these children had been prescribed auto-injectors.  The need for multiple doses in ED was less in those who received epinephrine outside ED.  [Allergy, Asthma & Clinical Immunology 2014, 10(Suppl 2):A3]

In a Canadian email survey of 1885 anaphylaxis survivors (adults and kids, food and insect etc), 73% did not give epipen.  Most common reason for not giving, was that an antihistamine had been given first.  Only 28% gave reason as being that they did not have epipen! 13% judged reaction as mild.  41% of epipens were given by someone other than patient, mostly family of children.  53% of epipen users had previously used one before.  [simons, clark, camargo – JACI 2009:124;301 doi:10.1016/j.jaci.2009.03.050]

Failure to prescribe

In an online survey presenting 10 paediatric allergy case histories to paediatricians (all were severe, although only 1 case specifically mentioned anaphylaxis).  There was significant variability in prescribing practices. Although all allergists and generalists prescribed an autoinjector (94.4% and 92.6%, respectively) or would offer the patient a choice about autoinjectors (5.6% and 7.4%, respectively) in the case specifically mentioning anaphylaxis, many cases had almost no consensus on prescription of adrenaline autoinjector. The prescribing patterns of allergists and generalists showed no significant differences for 9 of the cases. For the remaining case, which described a child with oral allergy syndrome, all specialists (n=54, 100%) reported that they would not prescribe an autoinjector (in line with guidelines) compared with only 20 (74.1%) of generalists (p<0.001).  [Johnson MJ, Foote KD, Moyses HE et al. (2012) Practices in the prescription of adrenaline autoinjectors. Pediatric Allergy and Immunology 23: 124-7]

In a survey of all GPs in Scotland, 90% of the 613 respondents had prescribed adrenaline autoinjectors. However, only 49% of prescribers were confident in use of these devices, and only 17% had access to a trainer pen for demonstration to patients. If called upon in an anaphylactic emergency (experienced by 36% of respondents), only 50% of respondents would use the appropriate dose and 14% would use an inappropriate route of administration (subcutaneous or intravenous).  [Lowe G, Kirkwood E, Harkness S (2010) Survey of anaphylaxis management by general practitioners in Scotland. Scottish Medical Journal 55:11-4]

Failure to Use – Doctors

When scenarios presented to junior doctors (same questions posed 10 years earlier) – all recognized need for adrenaline in anaphylaxis scenario but dose often wrong and 25% gave adrenaline IV.  For non-anaphylactic scenarios, adrenaline frequently recommended eg inhaled peanut.  Not much improvement over decade.  [Postgrad Med J 2015;91:3-7 doi:10.1136/postgradmedj-2013-132181 ]

Editorial discusses how doctors know that adrenaline is required in anaphylaxis, but that this knowledge is often not translated into practice. Many of these doctors had had ALS training; most had not worked in an emergency department.  Simulation?  Australian experience.  Booster sessions?

Accidental self-injection

See accidental adrenaline self-injection.

Anaphylaxis – management

Management of anaphylaxis involves treating the acute emergency, in the community first (see adrenaline autoinjectors), then in hospital, and then arranging appropriate follow up.  See also anaphylaxis definition.

Hospital

APLS guidelines (updated 2021) on management of acute anaphylaxis from the United Kingdom Resuscitation Council.

No distinction between anaphylactic and anaphylactoid reactions – confusing and may lead to inadequate treatment. Patients taking beta blockers may have a more severe reaction and respond less well to adrenaline.

Adrenaline is the only evidence based treatment specified in the guidelines.  It is therefore the treatment of choice.  You could argue that anaphylaxis is the one condition in which the ABC approach is not appropriate – as soon as anaphylaxis is suspected, you should give intramuscular adrenaline, and then proceed to airway, breathing etc.

Adrenaline is underused. 34% of cases of anaphylaxis in Patel’s metanalysis did not receive adrenaline (my calculation from table III); 10% needed more than 1 dose [Patel JACI 2021]. In scenario based studies, adrenaline is often not given.

Adrenaline by the intramuscular route is safe. If in doubt, just give it! Dose is 0.15mg for under 6yrs, 0.3mg for 6-12yrs, 0.5mg for over 12.  This is slightly different from the adrenaline autoinjector dose the child may have been prescribed for home use.

Repeat within five minutes if there is no improvement or if the patient’s condition deteriorates – not based on any evidence!

New guideline does not mention steroids or antihistamines at all! But does include IV bolus with second dose IM adrenaline after 5 minutes. 

Posture emphasised in new guidance – Lie down with legs raised, or allow sitting up in semi-recumbent position if that helps breathing. Beware sitting up, standing and walking even if feeling better – reported trigger for cardiac arrest – so caution when transferring.

Consider doing tryptase level if unclear trigger or if doubt whether it is anaphylaxis or panic attack, at earliest opportunity then repeated at 1-2 hours, and ideally again at later date to check baseline (raised would suggest mastocytosis).

Refractory Anaphylaxis

After that, if still not improving, there is a new Refractory anaphylaxis guideline. 

  • Get expert help.  Intravenous adrenaline should only be given by experienced practitioner.
  • Give repeated IM doses of adrenaline, or if experienced, start low dose IV adrenaline infusion:
    • 1 mg (1 mL of 1 mg/mL [1:1000]) adrenaline in
      100 mL of 0.9% sodium chloride, ie 1:100 000.
    • Beware BP cuffs and piggy back lines that will interfere and potentially cause extravasation. 
    • Start at 0.5-1ml/kg/hr and titrate.
    • Use ECG monitoring. 
  • Use nebulised adrenaline for stridor, neb salbutamol for wheeze or bronchospasm. 
  • After that intubation, inhalational anaesthetics (good for bronchospasm), repeat fluid boluses.

Discharge

Before, advice was observe for 6-12 hours, or admit if child. Now this has been risk stratified, with 6-12 hour rule applying for most cases. Exceptions are:

  • 2hr discharge if a) good response (5-10 minutes), to b) single dose adrenaline, c) given within 30 mins PLUS complete resolution PLUS already trained and with 2 unused AAIs PLUS adequate supervision
  • At least 12 hours after resolution if any of:
    • severe, needed more than 2 doses adrenaline
    • severe asthma, or had severe respiratory compromise
    • possibility of ongoing absorption eg slow release medication
    • late at night or potential to not respond to any deterioration
    • areas where emergency care difficult
  • or in context of supervised challenge

No reliable way to predict biphasic reaction so this should be discussed and decision made by senior clinician.

Follow up

See NICE guideline CG134.

Basic principles are to not discharge too soon, in case of a biphasic attack, but just as importantly, to consider prevention of further episodes (which involves making a diagnosis), and giving the patient and their family the appropriate information and skills to deal with an unexpected further allergic reaction.

Liverpool study (adults and children, I presume) found IM adrenaline given in 91.7% of cases, recommended observation period (6–12 h) achieved in 91.7% of patients. Long-term management not great – adrenaline auto-injector prescriptions provided to 50% of patients, “structured patient education” documented in 17.9% of cases, and allergy clinic referrals in 42.9%.

Who needs an Adrenaline auto-injector?

EAACI position paper suggests:

  • Absolute indications:
    • Previous cardiovascular or respiratory reaction to a food, insect sting or latex.
    • Exercise induced anaphylaxis.
    • Idiopathic anaphylaxis.
    • Child with food allergy and co-existent persistent asthma.
  • Relative indications:
    • Any reaction to small amounts of a food (e.g. airborne food allergen or contact only via skin).
    • History of only a previous mild reaction to peanut or a tree nut.
    • Remoteness of home from medical facilities.
    • Food allergic reaction in a teenager.

Prescribing a pen is only part of the overall management: nothing worse than prescribing a pen and not properly discussing avoidance, or having a pen that does not get used when it should be, because it’s left at home or because no-one remembers how to use it or they are too scared to use it.

Referral to an allergist is highlighted.  According to a Mayo Clinic study, 35% of those referred by emergency department (ED) had an alteration in the diagnosis or suspected trigger after allergy/immunology follow up.  Either anaphylaxis was ruled out; or an unknown trigger was successfully identified; or the suspected trigger was ruled out.  Allergists are also good at identifying new triggers, different from the one suspected (JACI In Practice 2014)

How well is anaphylaxis managed by emergency departments?

In 1 study from Arkansas, n=187 patients (all under 19), food (44%) and stings (22%) were the main triggers, whereas 29% had no identifiable allergen. Only 47% (n = 87) received adrenaline in the ED and only 31% of those via the preferred IM route (the rest were treated subcutaneously). 61% received autoinjectors at discharge. Only 45% received an allergy referral. [Ped Emergency Care 2016] Similar results from Birmingham, Alabama in 2010.

Most cases of anaphylaxis are coded as “allergic reaction” rather than anaphylaxis, which suggests hospital statistics are likely to represent only a minority of the cases coming to hospital. In the study above, before the 2006 NIAID anaphylaxis guidelines, only 20% of cases were accurately coded.

Anaphylaxis

See also:

Anaphylaxis is usually defined as an acute systemic allergic reaction with compromise airways, breathing and/or circulation.  Systemic here means that the reaction is not limited to just one body system (skin, GI, respiratory etc) but spreads to others.  It is usually – but not exclusively – mediated by IgE-antibodies.

There are however 5 different international definitions – not all include systemic, and of course not all systemic are anaphylaxis (for example skin and gut, 2 systems, not usually called anaphylaxis – except 2016 NIAD/FAAD definition in US, which specifies “persistent gut symptoms”).  Respiratory involvement alone sometimes not called anaphylaxis by experts, even when treated as such! 3 definitions use “life threatening” but that is somewhat subjective and poses the danger of delaying appropriate management until the reaction is already advanced. 

Use of the word “anaphylactic” is discouraged in the Resus council guideline, unless talking about anaphylactic shock, as it is misused to describe patients at risk of anaphylaxis (they may describe themselves as such), whereas this is actually anyone with a type 1 allergy.  

Anaphylactoid reactions are immediate systemic reactions that mimic anaphylaxis but for which an IgE-mediated immune mechanism can not be established – most people don’t bother trying to make a distinction now.

Resuscitation Council definition (2021):

  • Sudden onset, rapid progression
  • Airway/breathing/circulation problems (not specified)
  • “Life threatening” includes:
    • hoarse voice, stridor
    • wheeze, work of breathing, cyanosis, fatigue
    • Signs of shock (presumably pale, clammy), low BP, confusion, reduced consciousness
    • (not tongue swelling or persistent cough)

EAACI task force anaphylaxis criteria (2007, from Sampson): any one of –

  • acute onset (up to several hours) skin/mucosa reaction (eg generalized hives, pruritus or flushing, swollen lips/tongue/uvula) plus respiratory or cardiovascular compromise eg dyspnoea, bronchospasm, stridor, hypoxia, hypotension, collapse
  • acute onset after exposure to likely allergen of at least 2 of: skin/mucosa changes, resp, cardio compromise, persistent GI (eg crampy abdo pain, vomiting)
  • hypotension after exposure to known allergen for that individual

Note that this definition talks about “compromise”, and the examples given are mostly signs that only a medical professional could identify!  This doesn’t help patients/parents.  It also allows for anaphylaxis with just skin and persistent GI symptoms (where likely allergen exposure).

anaphylaxis grading sampson peds 2003
Anaphylaxis grading Sampson 2003

In Sampson’s original 2003 criteria, he grades anaphylaxis into 5 types. 1 and 2 would not be considered anaphylaxis these days at all!

WAO 2020 revised definition, based on input from 15 different allergy societies – “highly likely when any 1 of -“

  • acute onset skin/mucosa plus one of airway/breathing compromise, circulation, severe GI, or
  • acute hypotension, laryngeal involvement, bronchospasm [specifically] after likely exposure, even without skin symptoms.

BSACI’s allergy plan includes as severe symptoms hoarseness, dysphagia but also:

  • persistent cough,
  • noisy breathing
  • tongue swelling
  • persistent dizziness, pale/floppy, suddenly sleepy

AAP also has cough, hoarse, PLUS severe vomiting and diarrhoea, “many hives”(!), agitation.

On logistic regression, confusion and incontinence were strongly associated with hypotension and hypoxia. Dizziness, vomiting, abdominal pain, dyspnea and chest/throat tightness had weaker, albeit significant, associations. Pre-existing lung disease was associated with an increased risk of hypoxia. [Journal of Allergy and Clinical Immunology Volume 114, 2004, 371-376]

In a survey of kids with anaphylaxis, the mean latent period was 15.4 (SD27.5) minutes, ie 95% will react within 90 minutes of exposure. The type of allergy does not predict the latency well; however, age is inversely related, with younger children having more gradual onset. GI and cardiovascular symptoms tended to come later than skin/respiratory. 60% of anaphylactic reactions occurred in the home, and 10% happened in health care environments. Males predominate, particularly with regards exercise induced and insect venom anaphylaxis [PEDIATRICS Vol. 101 No. 4 April 1998].

Biphasic anaphylaxis

About 20% to 30% of food-induced anaphylactic events have a biphasic or recurrent response, although only half of those severe. 90% of recurrent reactions within 12 hours. Delay in giving adrenaline increases risk of recurrence! Some anaphylactic reactions are persistent, going on for hours.

Recognition

Recognition of anaphylaxis can be poor by non-experts. It is sometimes assumed that anaphylaxis must be life threatening, and that it must be progressive to the point of shock/collapse. Well recognised that anaphylaxis can resolve without treatment in some cases. Some have called for anaphylaxis grading, such as Sampson’s, but this then undermines the basic distinction.

Equally, people will sometimes diagnosis anaphylaxis on the basis of severe facial swelling, or widespread rash, neither of which are criteria.

Part of the problem of course is that what parents report is not the medical terminology included under the definitions. Infants and toddlers are a particular problem, since they cannot describe what they feel, and hypotension/syncope are extremely late signs. In US study, 48% of caregivers recognized 1 or more less obvious symptoms of anaphylaxis only in retrospect [but that includes skin/tongue/GI symptoms: looking at table II, 15% recognised sudden behaviour change in retrospect, 11% cough/wheeze, 6% wobbly/lethargy, difficult to rouse – can’t add up though]– that lack of recognition may affect management by medical team.

US 2024 study (Handorf) proposes modified NIAID/FAAN criteria – swollen tongue/uvula/pharynx becomes respiratory, not mucocutaneous; adds cough, drooling, hoarse cry/voice to respiratory too; specifies gagging, spitting up, diarrhoea, back arching as GI; pallor, mottling, obtunded/lethargy, altered mental state as CVS. By these criteria, 52% of all ED visits in children under 5 then became “anaphylaxis” (includes those given that diagnosis by attendings plus some ambiguous cases determined by clinicians to be anaphylaxis). Attendings diagnosed anaphylaxis in 68% of cases, but falls to 59% in infants. Original NIAD/FAAN criteria have 85% sensitivity, but falls to 77% infants. Modified criteria 100% sensitive for infants; 96-98% of older children. Compared with NIAD/FAAN, modified criteria picked up 43% more CVS signs, and 32% respiratory. Only 5% increase in GI. No hypotension/syncope in infants/toddlers, as expected.

Epidemiology

UK hospital admissions for food anaphylaxis have increased by 6.6% each year between 1998 and 2018 for under 15s (about 3x increase over whole period). For other ages much lower increase. Possibly due to 4hr waiting time rules for emergency departments? Or NICE recommendation on observation after suspected anaphylaxis? Case fatality rate has gradually fallen over time. At least 46% of all deaths triggered by peanuts or tree nuts. Cow’s milk responsible for 26% of deaths in school aged children (and rising), which shows how serious it can be when you don’t grow out of it in infancy. About a quarter trigger unknown (no comment – presumably no details in coding, rather than actually unknown), peanut and tree nuts together about a third. AAI prescriptions over the same period have increased by 336%.

Commentary by authors talks about effects on family of food allergy diagnosis but then goes straight into reasons for overdiagnosis, either through self reporting, commercial pressures, even campaigning by allergy charities. They say it is a “familiar pattern” with sharp increases in softer indicators of allergy, but no increase in markers of severe disease, and that this is the case in other countries such as the US and Australia. They conclude that we live in an era of increasing concern and awareness, but not a food allergy epidemic.

Whether the data are reliable, is a whole other question. Anaphylaxis is not well recognized, treated or documented, and only cases that were admitted were included, so these cases are probably just a fraction of what is actually coming to emergency departments. That doesn’t matter so much if that fraction stays the same and you’re only interested in trends. But even the interpretation of their own data seems curiously sceptical – if it is true that allergy is no more common than it was at any time in the last 30 years, are we saying families in the past just didn’t bother bringing their children to hospital when they had anaphylaxis? Or just more likely to admit (as NICE guidance from 2011 encourages observation for at least 6 hours, although the authors themselves say this probably only produced a minor increase in cases)?

Falling rates in peanut/nut, better awareness esp industry? Whereas milk awareness low? Although milk allergy common in young children, 5% of deaths in adults still due to milk (and prob harder to spot than nuts in food).

Higher rates of food anaphylaxis admissions in boys before puberty (male-to-female ratio 1.6:1), but reverses from age 15 years onwards. Highest rates of admission and death in teenagers, but in this study this risk continues through into mid adulthood, so supports the idea that it’s not specifically “teenage behaviour” that increases risk, rather biological vulnerability. In children under 5, deaths rare even though highest rate of admission.

[Conrado, BMJ 2021]

Risk Factors

Fatal anaphylaxis rate is about 1 in ¼ million. Risk of hospital admission with anaphylaxis 1 in 10 000. More likely to die on way to hospital appointment!? Doesn’t mean we avoid driving. Important to see that there can be an “acceptable risk” of living with food allergy.

Although there are a range of associations, most of these are very weak, which makes them unhelpful, or even misleading.

There is also a difference between sensitivity and severity. Some children during food challenges may only start reacting after a relatively high threshold dose – but their reactions tend to be worse, not unexpectedly.

Exercise is an important factor esp in teenagers, can even (rarely) be the sole identifiable trigger! See Exercise-Induced Anaphylaxis.

Statistically, females have worse reactions. In mice, the difference appears to be due to effect of oestradiol on increased tissue expression of eNOS (one of the NO synthases).

Medication – eg beta blockers, NSAIDS may increase risk.

Sleep deprivation reduced threshold in UK TRACE peanut study!

Most food anaphylaxis related to nuts (including peanut) and milk, but this is partly just how frequent these allergies are and how frequently the foods are encountered.

Deaths

Mostly in children over 5, despite the fact that food allergies are more common under 5 and usually lessen with time. Families often assume risk is higher in young children, which is incorrect. Nearly all are in children with asthma. Of the 8 deaths between 1990 and 2000, 4 were due to milk, 2 peanut, 1 egg and 1 mixed (but see below for bigger study). Both the peanut deaths were in children over 13yrs. Children are over 250x more likely to die in road traffic accident, although this is hardly a fair comparison.

Mortality and morbidity higher where adrenaline not used – so education (patient, family and health care) important, specifically recognition and management, giving out allergy care plans.[https://doi.org/10.1016/j.anai.2017.06.004]

Fatal Anaphylaxis Registry – set up in 1994 by Dr Richard Pumphrey based at Manchester University NHS Foundation Trust. This is now evolving into a European wide anaphylaxis registry.

In 80% of fatal anaphylaxis cases [mixed causes], adrenaline not given before arrest, which suggests delayed administration could be a factor. Same study shows that adrenaline does not prevent death even when given before arrest.

Most cases were in people with no previous history of anaphylaxis [but how many nut+asthma, where higher risk recognised?]

Survival better if adrenaline given within 30 mins [1992 Sampson article NEJM].

1 death at 6 hours, despite repeated adrenaline. 1 death after intentional consumption, despite immediate epipen administration.

So avoidance and asthma management are arguably more important than providing adrenaline autoinjectors! [Pumphrey]

Differential

If test unexpectedly negative, wait and repeat test (anergy if recent reaction well known in drug allergy, less clear if relevant to food allergy).

Test with raw food rather than commercial product, in case relevant protein under-represented.

Where no cause identified consider:

Differential includes mast cell disorders, asthma, panic attacks, conversion disorder, globus hystericus, vocal cord dysfunction, scombroid poisoning, vasoactive amine intolerance, carcinoid syndrome and phaeochromocytoma. 

Haemophagocytic syndromes

A group of disorders, including haemophagocytic lymphohistiocytosis, Macrophage activation syndrome, and PIMS-TS. Suspect when these unexplained or unusually severe, particularly in combination:

Prevention of peanut allergy

Use of peanut oil in eczema creams had OR 8 for peanut allergy but retrospective.

Filaggrin deficiency has OR 5 for food allergy, only 3 for eczema!

So could skin protection (particularly in babies with eczema) before early weaning prevent food allergy? Preliminary studies suggest 35- 50% response. Evidence that peanut consumption of household predicts peanut allergy in baby – presumably by skin sensitization.

Bamba peanut snack

Jewish children in the UK have a prevalence of peanut allergy that is 10-fold higher than that of Jewish children in Israel. This difference is not accounted for by differences in atopy, social class, genetic background, or peanut allergenicity. Israeli infants consume peanut in high quantities in the first year of life, Bamba (peanut snack, like a Wotsit) often used for weaning, so most infants have been exposed by age 12 months. [Du Toit  J Allergy Clin Immunol. 2008 Nov;122(5):984-9]

Gideon Lack at Evangelina hospital in London did LEAP study (Learning about Peanut Allergy), randomized infants with severe eczema and/or egg allergy to receive either no peanut until age 3yr, else an age-appropriate peanut snack (Bamba or smooth peanut butter, 6g) three times a week.   Among the 530 infants in the intention-to-treat population who initially had negative results on the skin-prick test, the prevalence of peanut allergy at 60 months of age was 13.7% in the avoidance group and 1.9% in the consumption group (86% reduction, P<0.001). 98 participants had baseline positive SPT results, only 12% had a positive challenge so most continued the protocol.  Another 10% with SPT>4mm were excluded from the start.

Adherence to the diet was excellent.  Dust samples were taken from some participants’ beds, peanut levels were significantly higher for kids in consumption group.  There was a higher rate of urticaria in the consumption group.

IgE greater than 10 in peanut avoiding group had 100% PPV for allergy.  Peanut-specific IgG4 antibody seems to be linked to tolerance – it went up more in the consumption group, and IgG4:IgE ratio was generally lower in allergic group (most had IgG4 under 1000). [NEJM 2015; DOI: 10.1056/NEJMoa1414850]  See also LEAP-On study, which is the follow up at 72 months, still significant difference.

Michael Perkins’ EAT study of early introduction of 6 common allergens in non-high risk babies showed if strict adherence to protocol eg 2g weekly of peanut, then every case of peanut allergy could be prevented.

Risk of peanut allergy in high risk babies estimated to be about 14%. Cost benefit analysis suggests better to go for early introduction WITHOUT initial testing, as high rate of false positives. Yet in the US at least, lots of early screening happening (median number of foods tested =10!), rarely followed by oral challenge. If you tested every high risk baby in the US with IgE, it would cost $900m…